Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.
Nassiba TaibMaysaloun MerhiVarghese InchakalodySarra MestiriShereena HydroseKarama Makni-MaalejAfsheen RazaFairooz SahirFouad AziziParveen B NizamuddinQueenie FernandesZeenath Safira K M YoosufSalam AlmoghrabiLobna Al-ZaidanAlaaeldin ShablakShahab UddinCristina MaccalliMohammed Ussama Al HomsiSaid DermimePublished in: Journal of translational medicine (2023)
We conclude that the upregulation of both stemness and immune checkpoint markers by DAC treatment on CRC cells might represent a mechanism of immune evasion. In addition, induction of NY-ESO-1 may represent an immuno-therapeutic option in metastatic CRC patients. Finally, the combination of DAC and anti-PD-1/anti-PD-L1 antibodies treatment should represent a potential therapeutic intervention for this group of patients.
Keyphrases
- end stage renal disease
- ejection fraction
- stem cells
- chronic kidney disease
- poor prognosis
- newly diagnosed
- randomized controlled trial
- squamous cell carcinoma
- prognostic factors
- peritoneal dialysis
- induced apoptosis
- acute myeloid leukemia
- cell proliferation
- epithelial mesenchymal transition
- risk assessment
- signaling pathway
- long non coding rna
- binding protein
- human health